论文部分内容阅读
该研究旨在比较静脉注射尼卡地平或拉贝洛尔(食品和药物管理局建议的剂量)对控制急性高血压的安全性和有效性。该研究为多中心随机临床试验。符合入选条件的患者均有2次收缩压测量值≥180mmHg以及对尼卡地平或拉贝洛尔没有禁忌。随机临床试验之前,医生事先设定一个血压达标范围(达标收缩压
The aim of the study was to compare the safety and efficacy of intravenous nicardipine or labetalol (recommended by the Food and Drug Administration) in the control of acute hypertension. This study is a multicenter randomized clinical trial. Patients who met the inclusion criteria had 2 systolic blood pressure measurements ≥ 180 mm Hg and no contraindications to nicardipine or labetalol. Before a randomized clinical trial, the doctor pre-set a blood pressure range (standard systolic blood pressure